This study aimed to establish a national reference standard for the purified Vi typhoid vaccine. The first national standard for the typhoid vaccine established in 2009 is currently outdated; hence, Boryung Biopharma Co. produced 4,070 vials of a candidate vaccine as per the second standard outlined in 2018. The large-scale manufacture of the standard candidate was guaranteed through quality tests and accelerated and long-term stability tests. Reference standards ensure the accuracy and reliability of the results of quality control tests for vaccines. Thus, a collaborative study was conducted to estimate the potency of the candidate material as per the second national standard using the test methods of HPAEC-PAD (High Performance Anion-Exchange Chromatography with Pulsed Amperometric Detection) and rocket immunoelectrophoresis. The HPAEC-PAD result was 51.5 μg/vial (95% confidence interval [CI]: 50.70-52.29 μg/vial). On the other hand, the rocket assay result was 63.4 μg/vial (95% CI: 61.08-65.89 μg/vial). In addition, the precision and proficiency of the institutes was confirmed by the CV and robust Z-score, respectively. The candidate will be registered for use as the second national standard for the purified Vi typhoid vaccine after evaluating its long-term stability. After registration, it will contribute to securing the reliability and consistency of the quality control test results for typhoid vaccines by being used in the national release system and quality control of the manufacturer.
서 론(Introduction)
방 법(Methods)
결과 및 고찰(Results and Discussion)
결 론(Conclusion)